دورية أكاديمية
أعرض في EDS

Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine.

التفاصيل البيبلوغرافية
العنوان: Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine.
المؤلفون: Myeni SK; Molecular Virology Laboratory, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Leijs AA; Molecular Virology Laboratory, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Bredenbeek PJ; Molecular Virology Laboratory, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Morales ST; Molecular Virology Laboratory, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Linger ME; Molecular Virology Laboratory, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Fougeroux C; AdaptVac Aps, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark., van Zanen-Gerhardt S; Experimental Pathology Services Laboratory, Central Animal and Transgenic Facility, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Zander SAL; Experimental Pathology Services Laboratory, Central Animal and Transgenic Facility, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; Experimental Animal Pathology Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Sander AF; AdaptVac Aps, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark.; Centre for Translational Medicine and Parasitology, Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark., Kikkert M; Molecular Virology Laboratory, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
المصدر: Vaccines [Vaccines (Basel)] 2024 Jul 12; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: The SARS-CoV-2 pandemic and the emergence of novel virus variants have had a dramatic impact on public health and the world economy, underscoring the need for detailed studies that explore the high efficacy of additional vaccines in animal models. In this study, we confirm the pathogenicity of the SARS-CoV-2/Leiden_008 isolate (GenBank accession number MT705206.1) in K18-hACE2 transgenic mice. Using this isolate, we show that a vaccine consisting of capsid virus-like particles (cVLPs) displaying the receptor-binding domain (RBD) of SARS-CoV-2 (Wuhan strain) induces strong neutralizing antibody responses and sterilizing immunity in K18-hACE2 mice. Furthermore, we demonstrate that vaccination with the RBD-cVLP vaccine protects mice from both a lethal infection and symptomatic disease. Our data also indicate that immunization significantly reduces inflammation and lung pathology associated with severe disease in mice. Additionally, we show that the survival of naïve animals significantly increases when sera from animals vaccinated with RBD-cVLP are passively transferred, prior to a lethal virus dose. Finally, the RBD-cVLP vaccine has a similar antigen composition to the clinical ABNCOV2 vaccine, which has shown non-inferiority to the Comirnaty mRNA vaccine in phase I-III trials. Therefore, our study provides evidence that this vaccine design is highly immunogenic and confers full protection against severe disease in mice.
References: Lancet Respir Med. 2023 May;11(5):439-452. (PMID: 36780914)
Eur J Immunol. 1995 Mar;25(3):823-9. (PMID: 7705414)
Am J Trop Med Hyg. 2020 Sep;103(3):1215-1219. (PMID: 32723427)
Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815)
Cell. 2020 Aug 20;182(4):812-827.e19. (PMID: 32697968)
Vaccine. 2023 Mar 24;41(13):2101-2112. (PMID: 36870874)
Vaccine. 2023 Jun 19;41(27):4042-4049. (PMID: 37045682)
Cell. 2022 Mar 3;185(5):847-859.e11. (PMID: 35139340)
Nature. 2020 Dec;588(7836):E6. (PMID: 33199918)
J Virol. 2007 Jan;81(2):813-21. (PMID: 17079315)
Pharmaceutics. 2022 Jun 18;14(6):. (PMID: 35745873)
ScientificWorldJournal. 2022 Jan 11;2022:5578284. (PMID: 35069037)
J Natl Cancer Inst. 2020 Oct 1;112(10):1038-1046. (PMID: 32091594)
Vet Pathol. 2013 Nov;50(6):1007-15. (PMID: 23558974)
Lancet Microbe. 2023 Mar;4(3):e140-e148. (PMID: 36681093)
Emerg Microbes Infect. 2020 Dec;9(1):2433-2445. (PMID: 33073694)
Nat Commun. 2023 Feb 28;14(1):1141. (PMID: 36854765)
Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
Cell Host Microbe. 2020 Jul 8;28(1):124-133.e4. (PMID: 32485164)
Nat Commun. 2021 Jan 12;12(1):324. (PMID: 33436573)
J Nanobiotechnology. 2016 Apr 27;14:30. (PMID: 27117585)
Nat Immunol. 2020 Nov;21(11):1470. (PMID: 32879513)
Immunity. 2022 Oct 11;55(10):1764-1778. (PMID: 36049482)
Nat Commun. 2020 Nov 30;11(1):6122. (PMID: 33257679)
Lancet Microbe. 2023 May;4(5):e309-e318. (PMID: 36963419)
Front Immunol. 2022 Apr 05;13:857440. (PMID: 35479095)
Vaccines (Basel). 2020 Mar 20;8(1):. (PMID: 32244935)
Med Microbiol Immunol. 2023 Apr;212(2):165-183. (PMID: 35661253)
Nature. 2023 Feb;614(7946):22-25. (PMID: 36726000)
Cell. 2020 Jul 9;182(1):50-58.e8. (PMID: 32516571)
Nature. 2020 Jul;583(7818):830-833. (PMID: 32380511)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Front Immunol. 2022 Jul 25;13:964179. (PMID: 35958594)
Nat Med. 2023 Feb;29(2):358-365. (PMID: 36593393)
JAMA Netw Open. 2023 May 1;6(5):e2310650. (PMID: 37133863)
Bull Exp Biol Med. 2011 May;151(1):99-102. (PMID: 22442812)
PLoS Pathog. 2021 Jan 19;17(1):e1009195. (PMID: 33465158)
معلومات مُعتمدة: 1011005077 Corona Accelerated R&D in Europe (CARE) project; 101003608 European Union's Horizon 2020 research and innovation program Prevent-nCoV project; 952373 European Union's 2020 research and innovation program
فهرسة مساهمة: Keywords: ABNCoV2; K18-hACE2 transgenic mice; RBD-cVLP; SARS-CoV-2; cVLP-based COVID-19 vaccine candidate
تواريخ الأحداث: Date Created: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11281552
DOI: 10.3390/vaccines12070766
PMID: 39066404
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines12070766